GSK’s DoJ Settlement Links Executive Bonus To Continued Compliance
GlaxoSmithKline pleads guilty to marketing Paxil and Wellbutrin off-label and concealing Avandia safety data from FDA and resolves allegations of kickbacks involving nine drugs; ground-breaking corporate integrity agreement includes novel recoup of bonuses from execs if they or their subordinates engage in “significant misconduct.”
You may also be interested in...
$1.4b payment to settle investigation of marketing of opioid addition treatment is biggest for a pharma in several years.
Commission files complaint as it reaches $50m settlement with Reckitt Benckiser.
Decision to replace the rosiglitazone REMS’ distribution restrictions with prescriber training reflected a consensus opinion shared by leadership in three CDER offices, despite a poll of reviewers who participated in a June advisory committee meeting and favored eliminating the risk management program.